NCT04491942: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin), or Cisplatin and Gemcitabine for Advanced Solid Tumors With Emphasis on Urothelial Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase
Exclusions: Patients with progressing brain metastasis or leptomeningeal disease that requires treatment- see trial for details

Comments are closed.

Up ↑